|
1
|
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
|
Ann Oncol
|
2008
|
2.13
|
|
2
|
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
|
Br J Cancer
|
2009
|
1.75
|
|
3
|
Do medical students copy the drug treatment choices of their teachers or do they think for themselves?
|
Eur J Clin Pharmacol
|
2009
|
1.50
|
|
4
|
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
|
Invest New Drugs
|
2008
|
1.21
|
|
5
|
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
|
Br J Cancer
|
2008
|
1.07
|
|
6
|
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
|
Br J Cancer
|
2009
|
0.92
|
|
7
|
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
|
Ann Oncol
|
2006
|
0.91
|
|
8
|
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
|
Br J Cancer
|
2008
|
0.83
|